BR100 Increased By (0.95%)
BR30 Increased By (1.02%)
KSE100 Increased By (0.99%)
KSE30 Increased By (1.06%)
AGHA 6.38 No Change ▼ 0.00 (0%)
BECO 4.37 Increased By ▲ 0.02 (0.46%)
BML 62.97 Increased By ▲ 0.42 (0.67%)
BOP 31.41 Increased By ▲ 0.02 (0.06%)
CNERGY 11.78 Increased By ▲ 0.05 (0.43%)
CSIL 5.77 Decreased By ▼ -0.14 (-2.37%)
FCCL 61.95 Increased By ▲ 0.24 (0.39%)
FFL 14.84 Increased By ▲ 0.05 (0.34%)
FNEL 1.30 Increased By ▲ 0.06 (4.84%)
KEL 6.34 Increased By ▲ 0.02 (0.32%)
KOSM 5.82 Decreased By ▼ -0.08 (-1.36%)
LOTCHEM 24.80 Increased By ▲ 0.11 (0.45%)
MLCF 106.15 Increased By ▲ 2.22 (2.14%)
NBP 174.52 Increased By ▲ 1.20 (0.69%)
NCPL 52.21 Increased By ▲ 0.38 (0.73%)
NPL 54.86 Increased By ▲ 0.83 (1.54%)
OGDC 318.78 Increased By ▲ 2.91 (0.92%)
PACE 9.33 Increased By ▲ 0.07 (0.76%)
PAEL 35.80 Increased By ▲ 0.22 (0.62%)
PIBTL 14.23 Increased By ▲ 0.57 (4.17%)
PPL 229.75 Increased By ▲ 3.68 (1.63%)
PRL 81.23 Increased By ▲ 0.95 (1.18%)
PTC 46.79 Increased By ▲ 0.15 (0.32%)
SSGC 24.13 Increased By ▲ 0.31 (1.3%)
TBL 9.32 Increased By ▲ 0.08 (0.87%)
TELE 7.60 Increased By ▲ 0.05 (0.66%)
TPL 24.66 Increased By ▲ 0.12 (0.49%)
TPLP 12.91 Decreased By ▼ -0.08 (-0.62%)
TREET 26.51 Increased By ▲ 0.53 (2.04%)
TRG 53.75 Increased By ▲ 0.42 (0.79%)
By

LONDON: British pharmaceutical giant AstraZeneca on Tuesday vowed to keep investing and growing its business in the United States, ahead of President Donald Trump’s possible tariffs on the sector.

“Our company is firmly committed to investing and growing in the US,” chief executive Pascal Soriot said in an earnings statement, which also announced that first quarter profit had risen by over 30 percent to $2.92 billion.

The United States earlier in April opened the door to potential tariffs targeting pharmaceuticals, which have so far benefited from exemptions to Trump’s sweeping levies on imports from trading partners.

He has also imposed a series of sector-specific levies, slapping tariffs on imports of steel, aluminium and autos, before launching a “national security” investigation into pharmaceutical imports.

The United States is a key market for the pharmaceutical industry, with Soriot saying earlier in the year that he hoped that the United States will represent approximately half of AstraZeneca’s global revenue by 2030.

The pharmaceutical giant said on Tuesday it remains on track to achieve its total target of $80 billion in annual revenue by 2030.

Comments

Comments are closed for this article.